Business
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today
About this update from Krystal Biotech, Inc.
[{"type":"text","content":"PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14. Krish Krishnan, Chairman and Chief Executive Officer, will deliver a presentation and host investor meetings on September 13. A webcast of the presentation will be available here beginning at 2:30pm ET on Tuesday, September 13 and will be posted on the Investor section of the Company’s website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter. CONTACT:Investors and Media: Meg Dodge Krystal Biotech [email protected] Source: Krystal Biotech, Inc. \nSource: Krystal Biotech, Inc.","length":4440,"tagName":"div"}]